l e t t e r s Endometriosis is a common gynecological disease associated with pelvic pain and subfertility. We conducted a genome-wide association study (GWAS) in 3,194 individuals with surgically confirmed endometriosis (cases) and 7,060 controls from Australia and the UK. Polygenic predictive modeling showed significantly increased genetic loading among 1,364 cases with moderate to severe endometriosis. The strongest association signal was on 7p15.2 (rs12700667) for 'all' endometriosis (P = 2.6 × 10 -7 , odds ratio (OR) = 1.22, 95% CI 1.13-1.32) and for moderate to severe disease (P = 1.5 × 10 −9 , OR = 1.38, 95% CI 1.24-1.53). We replicated rs12700667 in an independent cohort from the United States of 2,392 selfreported, surgically confirmed endometriosis cases and 2,271 controls (P = 1.2 × 10 −3 , OR = 1.17, 95% CI 1.06-1.28), resulting in a genome-wide significant P value of 1.4 × 10 −9 (OR = 1.20, 95% CI 1.13-1.27) for 'all' endometriosis in our combined datasets of 5,586 cases and 9,331 controls. rs12700667 is located in an intergenic region upstream of the plausible candidate genes NFE2L3 and HOXA10.
l e t t e r s by considering all SNPs simultaneously through inference of distant relatedness from marker data and comparing it to case-control status (Online Methods). The proportion of variation in case-control status explained by the GWAS data was highly significant for both 'all' and stage B endometriosis ( Table 1 and Supplementary Table 2 ). The estimate for stage B endometriosis (0.34, s.e. = 0.04) was significantly higher than that for stage A endometriosis (0.15, s.e. = 0.04; Table 1 ).
We also assessed the genetic loading of the different stages using a prediction approach (Online Methods) 19 in which we used the Oxford data as a discovery set to identify increasingly large SNP sets ranked on their significance of association ('allele specific scores') and used these scores to predict disease status in target samples from QIMR. The discovery and target sets were then reversed ( Supplementary  Fig. 2) . Oxford 'all' endometriosis predicted endometriosis in the QIMR sample, with the smallest P value (P = 8.4 × 10 −6 ) obtained for a score set including ~75% of the SNPs (Fig. 1) . This result was highly significant, although the proportion of variance explained was small (maximum Nagelkerke r 2 of 0.007; 0.7% of the variance). For stage B cases, the proportion of variance explained by most score sets was higher; for example, the score set including the ~20% most associated SNPs (P = 3.5 × 10 −7 ) explained 1.3% of the variance, consistent with a greater (polygenic) genetic loading for stage B disease.
We performed two genome-wide association analyses stratified by dataset (QIMR and Oxford) using (i) 3,194 'all' endometriosis cases and (ii) 1,364 stage B cases, given their substantially greater genetic loading (Online Methods). For 'all' endometriosis, we observed the strongest signal for rs12700667 in an intergenic region on chromosome 7p15.2 (P = 2.6 × 10 −7 , OR = 1.22, 95% CI 1.13-1.32; Table 2 ). As predicted from our quantitative genetic analyses, we observed stronger signals of association across the genome for stage B disease compared to 'all' endometriosis ( Supplementary Fig. 3 ). The 7p15.2 signal for stage B endometriosis was considerably stronger, producing P = 1.5 × 10 −9 , OR = 1.38, 95% CI 1.24-1.53 ( Table 2 ) for rs12700667 and P = 6.0 × 10 −8 , OR = 1.34, 95% CI 1.21-1.49 for the nearby SNP rs7798431 (r 2 = 0.87). A second strong association was found for rs1250248 (2q35) within FN1 (P = 3.2 × 10 −8 ) ( Supplementary  Table 3 ). Results for the SNPs rs12700667, rs7798431 and rs1250248 remained genomewide significant after adjustment for multiple testing in the two non-independent genomewide association analyses using permutation (Online Methods). Only one of the permuted genome-wide association analyses produced an independent P value less than that observed for rs12700667 (P = 0.001). The SNPs rs12700667 and rs7798431 lie in a narrow region of strong LD (r 2 > 0.8) that extends approximately 48 kb. Following imputation using 1000 Genomes Project and HapMap data ( Fig. 2 and Supplementary Note) conditioning on the effect of rs12700667 in logistic regression analysis showed no other independent associations with 'all' or stage B endometriosis in the region.
In addition to the three genome-wide significant SNPs, we genotyped 70 SNPs that produced nominal evidence of association with 'all' (P < 1.0 × 10 −4 ) or stage B endometriosis (P <1.0 × 10 −4 in stage B and P <1.0 × 10 −3 in 'all' endometriosis analyses; Online Methods) in an independent IEC dataset comprising 2,392 self-reported surgically confirmed cases from the Nurses' Health Study II (NHSII) and 2,271 controls from GWAS of breast cancer 20 and kidney function from Table 3 ). There was no evidence (nominal P ≤ 0.05) for replication of rs12540248 (FN1) or association with the remaining 70 SNPs (Supplementary Table 3 ). Analysis of all 5,586 cases and 9,331 controls from the combined QIMR, Oxford and NHS cohorts further confirmed association between 'all' endometriosis and 7p15.2, producing P = 1.4 × 10 −9 , OR = 1.20, 95% CI 1.13-1.27 for rs12700667 and P = 1.1 × 10 −7 , OR = 1.18, 95% CI 1.11-1.25 for rs7798431 ( Table 2) . Although effect sizes from discovery datasets may be inflated 22 , the similarity of ORs for 'all' endometriosis in our discovery (GWAS) and replication datasets ( Table 2 ) suggests this type of bias has not played a major role. Assuming the estimated OR of 1.20 and allele frequency of 0.74 for the rs12700667 A allele, a multiplicative risk model and a population prevalence of 8% (refs. 10,21,23), the estimated percentage of 'all' endometriosis variance explained by rs12700667 was 0.36, or 0.69% of the estimated 51% heritability of endometriosis 9 .
The associated SNPs are located in a ~924-kb intergenic region containing at least one noncoding RNA (AK057379), predicted transcripts and regulatory elements, and a miRNA (hsa-mir-148a) ~88 kb upstream of rs12700667. The closest gene, NFE2L3, which is highly expressed in placenta, is located ~331 kb downstream of rs12700667. Two endometriosis candidate genes, HOXA10 and HOXA11 (refs. 24, 25) , encoding members of the homeobox A family of transcription factors that play a role in uterine development, lie ~1. 35 Mb downstream of this SNP.
Among reported candidate gene associations for endometriosis 14 , the only gene with P < 10 −3 for SNPs in the GWAS data was PGR on chromosome 11 ( Supplementary Table 3 ), but the result for the SNP in this gene was not significant in the replication stage. A recent genome-wide association scan in Japanese women reported significant association of endometriosis with rs10965235 (P = 5.8 × 10 −12 , OR = 1.44), located on chromosome 9p21, and possible associations with rs13271465 on 8p22 and rs16826658 on 1p36 (ref. 26 ). The Japanese GWAS did not report our 7p15.2 signal among their 100 top SNPs followed up for replication, but with 1,423 cases and 1,318 controls, they would have had only 13% power to detect the effect of rs12700667 with P ≤ 1.8 × 10 -4 (Online Methods). We found no evidence for association with rs10965235 (which is monomorphic in individuals of European descent, reflecting the different genetic (ancestral) backgrounds between the studies) or any other SNP in LD (r 2 > 0.5 in the HapMap Japanese JPT population) in the QIMR and Oxford data ( Supplementary Table 4 ). We also found no evidence of association with 8p22. We did find evidence for replication of rs7521902 on 1p36, which is close to WNT4, for both 'all' endometriosis (P = 9.0 × 10 −5 , OR = 1.16, 95% CI 1.08-1.25) and stage B cases (P = 7.5 × 10 −6 , OR = 1.25, 95% CI 1.13-1.38), with the stronger signal in stage B providing additional empirical evidence for the benefit in examining stage B cases. Importantly, a meta-analysis of the QIMR and Oxford 'all' endometriosis OR with the reported Japanese OR of 1.25 (95% CI 1.12-1.39) for rs7521902 produced a genome-wide significant P value of 4.2 × 10 −8 (OR = 1.19, 95% CI 1.12-1.27). The frequency of the rs7521902 risk allele (A) was 0.57 and 0.51 in the Japanese GWAS cases and controls, respectively, and 0.26 and 0.24 in our combined GWAS cases and controls, respectively. WNT4 is important for development of the female reproductive tract 27 , ovarian follicle development and steroidogenesis 28, 29 , making it a plausible biological candidate.
We have identified a new locus on chromosome 7p15.2 that is significantly associated with risk of endometriosis in women of European ancestry, and we confirm a previously reported suggestive association for SNPs close to the WNT4 locus. Our analyses also demonstrate a higher genetic loading for moderate to severe (stage B) endometriosis, and consistent with these results, we observed the strongest association signals with stage B disease. Our predictive modeling demonstrates that there are additional common variants contributing to risk for this disease and that future larger studies enriched for laparoscopically-confirmed moderate to severe cases will be better powered to identify risk loci and aberrant pathways contributing to the development of endometriosis.
URLs. ECR Browser, http://ecrbrowser.dcode.org/; SNPTESTv2, http://www.stats.ox.ac.uk/~marchini/software/gwas/snptest.html; 1000 Genomes Project, http://www.1000genomes.org/; HapMap, http://hapmap.ncbi.nlm.nih.gov/.
METhOdS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturegenetics/.
Note: Supplementary information is available on the Nature Genetics website.
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Genotypes for QIMR cases and controls were called with the Illumina BeadStudio software. Standard quality control procedures were applied as outlined previously (Supplementary Methods) 33 . Following exclusions, 509,138 SNPs (2,270 cases and 1,870 controls) remained in the QIMR dataset. Oxford case and WTCCC2 control genotypes for all SNPs on the Illumina 670-Quad BeadChip were called using Illuminus 34 . Following exclusions (Supplementary Note), 540,082 SNPs (924 cases and 5,190 controls) remained in the dataset. Post-quality-control genotype data from QIMR and Oxford were combined across 504,723 SNPs passing quality control measures in both datasets.
Proportion of variation explained by all markers and predictive modeling.
Using a new method 18 , we estimated the proportion of variation explained by all markers. As genotyping artifacts can severely bias these estimates, the SNP data were subjected to more restrictive quality control than that utilized for the genome-wide association analyses. SNPs with minor allele frequency <0.01, missing rates >0.001, P values for Hardy-Weinberg equilibrium <10 −4 , and non-autosomal SNPs were excluded. Individuals with missing rates >0.01, as well as one member of any pair of individuals with an estimated relationship >0.05, were also excluded. After quality control, 2,235 cases and 1,827 controls with 454,193 SNPs were used for analysis of the QIMR data, and 921 cases and 5,158 controls with 453,663 SNPs were used for analysis of the Oxford data (Supplementary Table 2 ). When combining the data, we first pruned the SNPs to a common set and excluded closely linked SNPs (with r 2 > 0.5 in sliding 50 SNP windows) using PLINK 35 . Again, one member of any pair of individuals with an estimated relationship >0.05 was excluded. The combined analysis included 3,154 cases, 6,981 controls and 203,826 SNPs ( Table 1) .
Estimation of variation explained by all SNPs on the observed scale.
Pairwise realized relationships were estimated as described previously 18, 36, 37 . Phenotypic observations (affected or unaffected, coded as 0 or 1) were modelled as a linear function of the sum of the additive effects due to all SNPs and residuals. For the combined analysis (QIMR and Oxford), cohort information was modeled as a covariate, which adjusts for the mean difference in the proportion of cases between the two cohorts. Variance components were estimated by residual maximum likelihood 38, 39 .
The proportion of variation in case-control status explained by all SNPs simultaneously does not represent heritability in the conventional sense. Firstly, the observations are on the risk scale, whereas heritability estimates for disease from pedigree data are usually parameterized on an underlying unobserved liability scale. Secondly, the proportion of cases in the study is not the same as the proportion of cases in the population, so the estimate we obtained is with respect to a case-control population and not the population at large. Thirdly, conventional heritability from pedigree data captures the additive genetic variation due to all causal variants, whereas we captured only the variation due to causal variants tagged by SNPs on the arrays. Despite these caveats, the comparison of the proportion of variation estimates and the resulting P values from stage A and stage B cases remains valid because the test statistics would not change after scale transformation and ascertainment correction.
Case status prediction. The aim of our prediction analysis was to evaluate the aggregate effects of many variants of small effect. We summarized variation across nominally associated loci into quantitative scores and related the scores to disease state in independent samples. Although variants of small effect (genotype relative risk of 1.05) are unlikely to achieve even nominal significance, increasing proportions of 'true' effects will be detected at increasingly liberal P value thresholds such as P < 0.1 (or, 10% of all SNPs), P < 0.2, etc. Using such thresholds, we defined large sets of allele-specific scores in the discovery sample of the Oxford dataset to generate risk scores for individuals in the target sample of the QIMR dataset. The term 'risk score' is used instead of 'risk' , as it is impossible to differentiate the minority of true risk alleles from non-associated variants. In the discovery sample, we selected sets of allele specific scores for SNPs with P < 0.01, P < 0.05, P < 0.1, P < 0.2, P < 0.3, P < 0.4, P < 0.5 and P < 0.75. For each individual in the target sample, we calculated the number of score alleles they possessed, each weighted by the log 10 OR from the discovery sample. To assess whether the aggregate scores reflected endometriosis risk, we tested for a higher mean score in cases compared to controls. Logistic regression was used to assess the relationship between target sample disease status and aggregate risk score. Nagelkerke's pseudo R 2 was used to assess the variance explained. Autosomal SNPs with minor allele frequency <0.01 and SNPs in high linkage disequilibrium were pruned, resulting in a set of 225,955 SNPs.
Genome-wide association analyses.
Although endometriosis is a condition exclusive to women, male and female controls were used in analyses of autosomal markers to maximize power, a method adopted previously in GWAS of breast cancer by the WTCCC 40, 41 . No significant allele frequency differences were detected between male and female controls. Moreover, the genome-wide significant SNPs rs12700667 (7p15) and rs7521902 (WNT4) showed no heterogeneity between male and female controls (P = 0.52 and P = 0.91, respectively). Cochran-Mantel-Haenszel (CMH) tests of association with 'all' endometriosis or stage B alone were conducted in PLINK 35 , with QIMR and Oxford data as different strata (to account for between population differences in baseline effect). Breslow-Day tests were conducted to check that the assumptions of the CMH test (that is, having the same effect size across strata) were true.
Permutation approach to correct for multiple testing. To address the nonindependence between the 'all' and stage B genome-wide association analyses, we utilized a permutation approach where case or control status was randomly shuffled separately within the QIMR and Oxford datasets to break the relationship between phenotype and genotype while retaining the relationship between 'all' and stage B endometriosis. Of the 1,000 permuted genome-wide associations, recording the minimum P value for each SNP after analysis of both 'all' and stage B cases, a P ≤ 6.5 × 10 −8 was obtained 50 times (genome-wide P ≤ 0.05). Hence, rs12700667, rs7798431 and rs1250248 remained genomewide significant after adjustment for multiple testing. Only one permuted genome-wide association produced an independent P value less than that observed for rs12700667 (P = 0.001, corrected for testing of both multiple markers and disease definitions).
Replication samples and genotyping. Endometriosis cases (n = 2,392) for the replication samples were drawn from the US Nurses' Health Study (NHS) II 21, 42 . Replication controls were selected from two previous GWAS conducted in the NHSI and NHSII, including 1,142 postmenopausal, breast-cancer-free subjects from a breast cancer GWAS genotyped using the Illumina HumanHap 550 platform 20 and 1,129 subjects from a GWAS for kidney function 43 genotyped using Illumina 610 BeadChips. Quality control procedures have been described previously 20 .
SNPs selected for replication were genotyped in the 2,392 NHS cases. Multiplex assays were designed using the Sequenom MassARRAY Assay Design software (version 3.0: Sequenom Inc.) and samples were genotyped using standard methods 44, 45 . Post-laboratory quality control filtering was performed with PLINK 35 .
Replication and meta-analyses. GWAS SNPs reaching genome-wide significance were tested for replication in the NHS cohort. Also, to help direct further studies, we examined SNPs if they surpassed the following thresholds:
